360 related articles for article (PubMed ID: 16098464)
21. Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells.
Nasreen N; Mohammed KA; Antony VB
Cancer; 2006 Nov; 107(10):2425-35. PubMed ID: 17041885
[TBL] [Abstract][Full Text] [Related]
22. Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.
Brantley-Sieders DM; Fang WB; Hwang Y; Hicks D; Chen J
Cancer Res; 2006 Nov; 66(21):10315-24. PubMed ID: 17079451
[TBL] [Abstract][Full Text] [Related]
23. EphA2 induction of fibronectin creates a permissive microenvironment for malignant cells.
Hu M; Carles-Kinch KL; Zelinski DP; Kinch MS
Mol Cancer Res; 2004 Oct; 2(10):533-40. PubMed ID: 15498927
[TBL] [Abstract][Full Text] [Related]
24. Ephrin-A1 inhibits NSCLC tumor growth via induction of Cdx-2 a tumor suppressor gene.
Sukka-Ganesh B; Mohammed KA; Kaye F; Goldberg EP; Nasreen N
BMC Cancer; 2012 Jul; 12():309. PubMed ID: 22824143
[TBL] [Abstract][Full Text] [Related]
25. APC inhibits ERK pathway activation and cellular proliferation induced by RAS.
Park KS; Jeon SH; Kim SE; Bahk YY; Holmen SL; Williams BO; Chung KC; Surh YJ; Choi KY
J Cell Sci; 2006 Mar; 119(Pt 5):819-27. PubMed ID: 16478791
[TBL] [Abstract][Full Text] [Related]
26. Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis.
Nakamoto M; Bergemann AD
Microsc Res Tech; 2002 Oct; 59(1):58-67. PubMed ID: 12242697
[TBL] [Abstract][Full Text] [Related]
27. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
[TBL] [Abstract][Full Text] [Related]
28. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.
Roberts PJ; Der CJ
Oncogene; 2007 May; 26(22):3291-310. PubMed ID: 17496923
[TBL] [Abstract][Full Text] [Related]
29. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
30. Expression and functional effects of Eph receptor tyrosine kinase A family members on Langerhans like dendritic cells.
Munthe E; Finne EF; Aasheim HC
BMC Immunol; 2004 Jun; 5():9. PubMed ID: 15176971
[TBL] [Abstract][Full Text] [Related]
31. Ras-mediated intestinal epithelial cell transformation requires cyclooxygenase-2-induced prostaglandin E2 signaling.
Repasky GA; Zhou Y; Morita S; Der CJ
Mol Carcinog; 2007 Dec; 46(12):958-70. PubMed ID: 17477350
[TBL] [Abstract][Full Text] [Related]
32. Expression of Eph receptors and their ligands, ephrins, during lipopolysaccharide fever in rats.
Ivanov AI; Steiner AA; Scheck AC; Romanovsky AA
Physiol Genomics; 2005 Apr; 21(2):152-60. PubMed ID: 15671251
[TBL] [Abstract][Full Text] [Related]
33. Phosphoproteomic profiling of NSCLC cells reveals that ephrin B3 regulates pro-survival signaling through Akt1-mediated phosphorylation of the EphA2 receptor.
Ståhl S; Branca RM; Efazat G; Ruzzene M; Zhivotovsky B; Lewensohn R; Viktorsson K; Lehtiö J
J Proteome Res; 2011 May; 10(5):2566-78. PubMed ID: 21413766
[TBL] [Abstract][Full Text] [Related]
34. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N
Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953
[TBL] [Abstract][Full Text] [Related]
35. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
Niu G; Carter WB
Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
[TBL] [Abstract][Full Text] [Related]
36. Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior.
Carles-Kinch K; Kilpatrick KE; Stewart JC; Kinch MS
Cancer Res; 2002 May; 62(10):2840-7. PubMed ID: 12019162
[TBL] [Abstract][Full Text] [Related]
37. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines.
Hollestelle A; Elstrodt F; Nagel JH; Kallemeijn WW; Schutte M
Mol Cancer Res; 2007 Feb; 5(2):195-201. PubMed ID: 17314276
[TBL] [Abstract][Full Text] [Related]
38. Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis.
Cui XD; Lee MJ; Kim JH; Hao PP; Liu L; Yu GR; Kim DG
Hepatology; 2013 Jun; 57(6):2248-60. PubMed ID: 23315987
[TBL] [Abstract][Full Text] [Related]
39. Restriction of receptor movement alters cellular response: physical force sensing by EphA2.
Salaita K; Nair PM; Petit RS; Neve RM; Das D; Gray JW; Groves JT
Science; 2010 Mar; 327(5971):1380-5. PubMed ID: 20223987
[TBL] [Abstract][Full Text] [Related]
40. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.
Ferluga S; Hantgan R; Goldgur Y; Himanen JP; Nikolov DB; Debinski W
J Biol Chem; 2013 Jun; 288(25):18448-57. PubMed ID: 23661698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
